Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study

Table 1

Patient flow for the policy cohort and the three historical cohorts.

	Policy cohort	Historical cohorts
	2019	2016	2017	2018
Inclusion criteria^†
Number of users of originator infliximab^‡	3,179	3,273	3,363	3,328
Number of patients with an inflammatory bowel disease	2,674	2,637	2,780	2,783
Exclusion criteria, n (%) of patients excluded^†
Low compliance/discontinuers	97 (3.1)	119 (3.6)	125 (3.7)	157 (4.7)
Switchers	24 (0.8)	7 (0.2)	7 (0.2)	9 (0.3)
Lack of enrollment	20 (0.6)	28 (0.9)	28 (0.8)	33 (1.0)
No PharmaCare	694 (21.8)	115 (3.5)	378 (11.2)	590 (17.7)
Patients in the final cohort, n	1,839	2,368	2,242	1,994

^†Criteria are listed in Supplementary Table 2.
^‡Brand name Remicade.
The policy cohort comprised individuals with a prescription for originator infliximab during a 6-month identification period between March 7, 2019 and September 4, 2019, the day before policy introduction. The three historical cohorts consisted of individuals with a prescription for the originator infliximab during 6-month identification periods between March 7 and September 4, 2016, 2017, and 2018.